Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: Clin Cancer Res. 2014 Mar 14;20(10):2740–2750. doi: 10.1158/1078-0432.CCR-13-2507

Figure 5. In vivo therapeutic and biological effects of PDGFRα blockade on uterine cancer.

Figure 5

A, In vivo therapeutic effect of PDGFRα blockade on uterine cancer. Mice inoculated with Ishikawa, Hec-1A, Spec-2, or OVCA432 cells received PBS (control), 3G3 (a monoclonal antibody to human PDGFRα), chemotherapy (100 µg/mouse of paclitaxel or 30 µg/mouse of docetaxel), or a combination of 3G3 and chemotherapy 2 weeks following cell injection. Animals from all groups were euthanized when control animals became moribund (4–5 weeks after initiating therapy, depending on the cell line used). All tumors were harvested; mean tumor weight, number of nodules, and their distribution were recorded. Columns mean tumor weights for each group; Error bars, SEM. * P < 0.05. B, In vivo biological effects of PDGFRα blockade on expression of PDGFRα, pPDGFRα, pAKT, and pMAPK; tumor cell proliferation (Ki67); angiogenesis (CD31); and apoptosis (TUNEL). Immunohistochemical stains were performed on Hec-1A cell-bearing mice. Error bars, SEM. *, P < 0.05 compared to control. **, P < 0.05 compared to chemotherapy-alone group.